Meighan PC , Meighan SE , Rich ED , Brown RL , Varnum MD .

EY12836 NEI NIH HHS , EY19907 NEI NIH HHS , R01 EY012836 NEI NIH HHS , R01 EY019907 NEI NIH HHS

	Figure 1. MMP9 increases the ligand sensitivity of CNGA3 homomeric channels. (A) Representative current traces from inside-out patches excised from Xenopus oocytes expressing homomeric human CNGA3 (A3) after activation by a sub-saturating concentration of cGMP (2 μM) for control (top) and ~10 nM MMP9-treated (bottom) patches immediately (t0, dashed line) and 60 min (t60, dark line) following excision. Current traces were elicited using voltage steps from a holding potential of 0 mV, to +80 mV, -80 mV and then returning to 0 mV. (B) Representative dose-response curves for activation of control (open symbols) and MMP9-treated (closed symbols) channels by cGMP at t0 (circles) and t60 (squares). Currents were normalized to the maximum t0 cGMP current. Continuous curves (t0, solid line; t60, hashed line) represent fits of the dose-response relationship to the Hill equation as indicated in materials and methods. Parameters for each condition shown are as follows: control, K1/2,t0 = 6.6 μM, nH = 2.9, IMAX = 1.0, K1/2,t60 = 10.3 μM, nH = 2.1, IMAX = 1.0; MMP9 K1/2,t0 = 6.4 μM, nH = 2.5, IMAX = 1.0, K1/2,t60 = 0.7 μM, nH = 1.1, IMAX = 0.8. (C) Time course for the change in cGMP apparent affinity for control (open circles) and MMP9-treated (filled circles) patches following excision. Data based on best fit Hill curves and expressed as mean K1/2 (± S.E.M.). (D) Representative current traces after activation by a saturating concentration of cGMP (1 mM, black line) or cAMP (10 mM, gray line) for control (top) and MMP9-treated (bottom) patches at 60 min following excision. (E) Time course for the change in cAMP efficacy for control (open circles) and MMP9-treated (filled circles) patches following excision. (F) Representative dose-response relationships for activation of control (open symbols) and MMP9 treated (closed symbols) A3 channels by cAMP at t0 (circles) and t80 (squares). Currents were normalized to the maximum cGMP current. Parameters of best fit Hill curves (t0, solid line; t80, hashed line) for each condition shown are as follows: control, K1/2,t0 = 1.0 mM, nH = 1.1, IMAX = 0.29, K1/2,t80 = 0.9 mM, nH = 1.0, IMAX = 0.14; MMP9 K1/2,t0 = 1.2 mM, nH = 2.2, IMAX = 0.26, K1/ 2,t80 = 0.4 mM, nH = 1.4, IMAX = 0.74. (G) Summary of change in cAMP apparent affinity for control (open circles) and MMP9-treated (filled circles) patches. (H) Families of current traces elicited by voltage steps from -100 mV to +100 mV, recorded in the presence of 1 mM cGMP, for control (top) and MMP-treated (bottom) patches at 60 min following excision. (I) Mean (± S.E.M.) current-voltage (I-V) relationships for control (open symbols) and MMP9-treated (filled symbols) patches at t0 (circles) and t60 (squares).
	Figure 2. Single channel activity of MMP9 treated CNGA3 homomeric channels. Representative traces from an inside-out patch containing three CNG channels at cGMP concentrations of 5 µM (A), 0.5 µM (B) and 0 (C) at 5 min (t5, left column) and ~30 min (t30, right column) following excision. Currents were elicited at a membrane potential of +80 mV. C, closed channel mean current level; O, current level(s) for open channel(s). Current-amplitude histograms were amassed from 4–6 sec of recording and fit by either a single Gaussian function or the sum of multiple Gaussian functions (as indicated). The open probabilities (PO) for the different cGMP concentrations are as follows: (A) 5µM cGMP, PO,t5 = 0.11, PO,t30 = 0.43; (B) 0.5 µM cGMP, PO,t5 < 0.01, PO,t30 = 0.20 (C) 0 cGMP, PO,t5 < 0.01, PO,t30 = 0.06. The best-fit Gaussian curves produced the following unitary current (i) amplitude estimates: it5 = 2.5 pA; it30 = 3.4 pA. Scale bars: 50 msec; 5 pA.
	Figure 3. Inhibition of catalytic activity attenuates MMP9 induced gating effects. (A) (Left) Time course of the change in K1/2 cGMP for control (open circles) and MMP-treated patches with varying levels of calcium chelation as indicated in Materials and Methods (calcium free, squares; standard calcium, diamonds; elevated calcium, circles). (Right) Box plots summarize the K1/2, cGMP change as ratios between the initial (t0) and 20 min (t20) values (boxes represent 25th to 75th percentiles, lines represent the median, and whiskers represent the 5th to 95th percentiles). Increasing concentration of free calcium significantly enhanced the K1/2, cGMP change [single-factor ANOVA (n = 6), p < 0.0001, Holm’s t-test, *p < 0.05, ***p < 0.01]. (B) (Left) Time course of the change in cAMP efficacy for control (open circles) and MMP-treated patches with varying levels of free calcium [filled symbols, as in (A)]. (Right) Box plots summarizing the change in cAMP efficacy from the initial value at 20 min post excision. Increasing the concentration of free calcium significantly increased cAMP efficacy (p < 0.0001, single-factor ANOVA, n = 6; *p < 0.05, Holm’s t-test). (C) Box plots summarizing the change in K1/2, cGMP (Left) and the change in cAMP efficacy (Right) approximately 25 min post excision. Coapplication of a function-blocking antibody with MMP9 (MMP + Ab) or heat denaturation of MMP9 (MMP + heat) significantly reduced the effect of MMP9 on gating (p < 0.0001, single-factor ANOVA, n = 3–6; *p < 0.05, **p < 0.01, ***p < 0.001, Holm’s t-test;).
	Figure 4. Disruption of the actin cytoskeleton or of integrin mediated cell adhesion does not prevent MMP9 induced gating effects. (A) Box plots summarizing the change in K1/2, cGMP (Left) and the change in cAMP efficacy (Right) approximately 25 min post excision. Neither the integrin adhesion peptide antagonist GRGDSP (MMP+RGD), nor disruption of the actin cytoskeleton by cytochalasin D, significantly altered the change in K1/2, cGMP or in cAMP efficacy induced by MMP9 (p > 0.1, single-factor ANOVA analysis performed among MMP9-treatment conditions, n = 4–7). (B) Representative dose-response curves for activation of control (open squares), and protease treated (filled symbols) A3 channels by cGMP at t40 (Left). Currents were normalized to the maximum t40 cGMP current. Parameters of best fit Hill curves for each condition shown are as follows: control, K1/2 = 8.0 μM, nH = 2.3; MMP9 (filled squares), K1/2 = 0.4 μM, nH = 1.3; MMP2 (filled diamonds), K1/2 = 0.5 μM, nH = 1.2; trypsin (filled triangles), K1/2 = 10.0 μM, nH = 1.9; collagenase (filled circles), K1/2 = 8.6 μM, nH = 2.3. Box plots summarizing the change in K1/2, cGMP approximately 40 min post excision (Right). MMP2 (10 nM) produced gating effects indistinguishable from MMP9 (10 nM). Application of either trypsin (10 nM) or collagenase (100 nM) failed to produce similar gating effects
	Figure 5. MMP9 directed gating effects are influenced by channel state. (A) (Left) Time course of the change in K1/2, cGMP for control (open circles) and MMP-treated patches exposed to varying concentrations of cGMP to influence channel state: open (1 mM cGMP), squares; closed (zero cGMP), circles; sub-saturating cGMP (graded, 0.2–2 µM), diamonds. (Right) Box plots summarize the K1/2, cGMP change as ratios between the initial (t0) and 20 min (t20) values. Exposure to cGMP significantly impacted the MMP9 induced K1/2, cGMP change (p < 0.0001, single-factor ANOVA, n = 4–5). Individual comparisons demonstrate that maintaining channels in the open state significantly attenuated the K1/2, cGMP change, whereas exposure to sub-saturating cGMP significantly enhanced the K1/2 change compared with the closed state (**p < 0.01, Holm’s t-test, n = 4–5). (B) (Left) Time course of the change in cAMP efficacy for control (open circles) and MMP9-treated patches exposed to varying levels of cGMP [filled symbols, as in (A)]. (Right) Box plots summarize the change in cAMP efficacy at 10 min post excision compared with the initial value. Exposure to cGMP significantly impacted the change in cAMP efficacy (p < 0.01, single-factor ANOVA, n = 4–5). The efficacy of cAMP was significantly elevated after 10 min for patches exposed to sub-saturating cGMP (*p < 0.05, Holm’s t-test, n = 4–5).
	Figure 6. Rate of ligand-sensitivity change is sensitive to channel density. (A) Representative time course demonstrating the change of current in the presence of a sub-saturating concentration of cGMP (2 μM) for control (open diamonds) and 10 nM MMP9 treated (filled diamonds) patches immediately following excision. The 2 μM current was normalized to the saturating cGMP current (IMAX). Shaded area highlights the linear phase of the gating change. (B) Scatter plot of the linear phases of representative time courses with varying channel densities for patches treated with MMP9. Data expressed as the change in the 2 μM current density (ΔIρ). Approximate channel densities for each time course (listed on right) were calculated with membrane patch area estimates.84 Gray lines represent linear fits, with the following best-fit slopes: (in ascending order, pA•(μm2 • sec)−1) 0.0046, 0.043, 0.12, 0.30 and 0.33. (C) Best-fit slopes were plotted against the estimated channel densities for MMP9 treated patches and fit with the Michaelis-Menten equation with the following best-fit parameters and 95% confidence intervals: KM = 177 ± 26 channels; VMAX = 0.5 ± 0.03 pA•(μm2 • sec)−1.
	Figure 7. Application of MMP2 and -9 promotes proteolysis of CNGA3 subunits. Western blot analysis is shown for protein lysates from oocytes expressing FLAG-CNGA3 subunits. Intact oocytes were treated with MMP2 and -9 (100 μg/mL total) for 1 h; protein immunoreactivity was assessed using anti-FLAG antibody. MMP9/2 exposure caused a decrease in the bands associated with the full-length CNGA3 subunit (dark arrow) and a corresponding increase in a lower molecular weight form (gray arrow). The blot image was divided into two sections; the upper section had a shorter film-exposure time than the lower section.
	Figure 8. MMP9 increases the ligand sensitivity of heteromeric CNGA3 + CNGB3 channels. (A) Representative dose-response curves for activation of control (open symbols) and MMP9 treated (closed symbols) A3+B3 channels by cGMP at t0 (circles) and t80 (squares). Currents were normalized to the maximum t0 cGMP current. Shaded area represents approximate physiological cGMP concentration in photoreceptors in the dark.47 Although prolonged MMP exposure decreases the maximum current in the presence of cGMP (IMAX), channel activation by an approximately physiological concentrations of cGMP is enhanced for MMP-treated patches. Parameters of best fit Hill curves (t0, hashed line, t80; solid line) for each condition shown are as follows: control, K1/2,t0 = 15.7 μM, nH = 2.1, IMAX = 1.0; K1/2,t80 = 16.5 μM, nH = 1.9, IMAX = 0.94; MMP9, K1/2,t0 = 15.2 μM, nH = 2.2, IMAX = 1.0; K1/2,t80 = 3.6 μM, nH = 0.8, IMAX = 0.75. (B) Time course for the change in cGMP apparent affinity for control (open circles) and MMP9-treated (filled circles) patches following excision. (C) Representative current traces after activation by a sub-saturating concentration of cGMP (2 μM) for control (top) and MMP9-treated (bottom) patches immediately (t0) and 80 min (t80) following excision. (D) Time course of the 2 μM current for control (open diamonds) and MMP9 treated (filled diamonds) patches following excision. Current normalized to maximal cGMP current (IMAX). (E) (left) Representative time course for current deactivation following removal of a saturating concentration of cGMP (1 mM; black bar) for an MMP treated patch within 5 min (open circles) and approximately 40 min following excision (t40; filled circles). Both groups were normalized to their maximum cGMP current and fit with a single exponential-decay function (black lines) with the following best-fit time constants: τt5 = 5.1 sec; τt4o = 11.2 sec. The use of a double-exponential function produced a significantly better fit than the single exponential for the t40 group (gray line; p < 0.001, extra sum-of-squares F-test) with the following decay constants: τfast = 6.2 sec; τslow = 48.5 sec. Box plots summarizing the change in the persistent current (no cNMP) within 40 min of excision for MMP-treated and control patches (right). Persistent currents were normalized to the maximum cGMP elicited current for each time point. Treatment with MMP9 produced an increase in the persistent current (*p < 0.05, Student's t-test, n = 6).
	Figure 9. MMP9 increases the ligand sensitivity of rod homomeric CNGA1 and heteromeric CNGA1 + CNGB1 channels. (A) Representative dose-response curves for activation of control (open symbols) and MMP9 treated (closed symbols) A1 channels by cGMP at t0 (circles) and t40 (squares). Currents were normalized to the maximum t0 cGMP current. Parameters of best fit Hill curves (t0, hashed line; t40, solid line) for each condition shown are as follows: control, K1/2,t0 = 75.9 μM, nH = 2.2, IMAX = 1.0, K1/2,t40 = 43.9 μM, nH = 2.2, IMAX = 1.0; MMP9 K1/2,t0 = 75.3 μM, nH = 1.8, IMAX = 1.0, K1/2,t40 = 1.5 μM, nH = 0.9, IMAX = 0.50. (B) Time course for the change in cGMP apparent affinity of A1 channels for control (open circles) and MMP9-treated (filled circles) patches following excision. (C) Representative cGMP dose-response curves of control (open symbols) and MMP9 treated (closed symbols) A1+B1 channels at t0 (circles) and t40 (squares). Currents were normalized to the maximum t0 cGMP current. Parameters of best fit Hill curves (t0, hashed line; t40, solid line) for each condition shown are as follows: control, K1/2,t0 = 59.4 μM, nH = 2.3, IMAX = 1.0, K1/2,t40 = 55.6 μM, nH = 2.4, IMAX = 0.75; MMP9 K1/2,t0 = 57.2 μM, nH = 2.3, IMAX = 1.0, K1/2,t40 = 3.9 μM, nH = 1.5, IMAX = 0.53. (D) Time course for the change in cGMP apparent affinity of A1+B1 channels for control (open circles) and MMP9-treated (filled circles) patches following excision.
	Figure 10. MMP9 induced gating effects are more pronounced for homomeric compared with heteromeric rod and cone CNG channels. (A) Representative dose-response curves for activation of control (open symbols) and MMP9-treated (closed symbols) A3 homomeric (diamonds) and A3+B3 heteromeric (triangles) channels by cGMP, at 80 min post excision. Currents were normalized to the maximum cGMP current. Continuous curves (A3, solid line; A3+B3, hashed line) represent fits with the allosteric model described in Materials and Methods. The best fit equilibrium constants for the allosteric transition (L) for each condition shown are as follows: A3control = 180, A3MMP = 217000; A3+B3control = 90, A3+B3MMP = 1700. (B) Representative dose-response curves for activation of control (open symbols) and MMP9-treated (closed symbols) A1 homomeric (diamonds) and A1+B1 heteromeric (triangles) channels by cGMP at 40 min post excision. Currents were normalized to the maximum cGMP current. Continuous curves (A1, solid line; A1+B1, hashed line) represent fits with the allosteric model used in (A). The best fits of L for each condition are as follows: A1control = 40, A1MMP = 5400; A1+B1control = 20, A1+B1MMP = 1700. (C) Bar graph showing the change in free energy difference of the allosteric transition associated with the maximal MMP9 induced gating effects for rod and cone homomeric and heteromeric channels; data expressed as mean (± S.E.M.). The change in free energy difference for channel gating was significantly reduced for heteromeric channels compared with homomeric channels [p < 0.001, 2-factor ANOVA, (channel type)] X (subunit heterogeneity), independent effect of (subunit heterogeneity), n = 3–7].
	Figure 11. MMPs enhance the ligand sensitivity and apparent proteolysis of native rod photoreceptor CNG channels. (A) MMP9 (10 nM) was applied to the extracellular face of inside-out patches excised from Xenopus rod outer segments. Representative dose-response curves are shown for activation of control (open symbols) and MMP9-treated (closed symbols) rod CNG channels by cGMP at t0 (circles) and t25 (squares). Currents were normalized to the maximum t0 cGMP current. Parameters of best fit Hill curves (t0, hashed line; t25, solid line) for each condition shown are as follows: control, K1/2,t0 = 19.3 μM, nH = 2.6, IMAX = 1.0, K1/2,t25 = 28.1 μM, nH = 2.6, IMAX = 0.70; MMP9, K1/2,t0 = 22.8 μM, nH = 2.0, IMAX = 1.0, K1/2,t25 = 4.9 μM, nH = 1.3, IMAX = 0.41. (B) Representative current traces after activation by a saturating concentration of cGMP (1 mM, black line) or cAMP (10 mM, gray line) for control (top) and MMP9-treated (bottom) patches at approximately 25 min following excision. (C) Box plots summarizing the change in K1/2 cGMP (Left) and the change in cAMP efficacy (Right) approximately 25 min post excision. Exposure to MMP9 significantly reduced the K1/2 cGMP and enhanced the efficacy of cAMP relative to controls (**p < 0.01, Student’s t-test, n = 3). (D) Application of MMP2 and -9 promotes proteolysis of native rod CNGA1 subunits in a pattern that mimics existing in vivo proteolytic processing. Western blot analysis is shown of detergent-soluble protein homogenates from mouse retina of “young” (Y, 2–3 mo old) and “old” (O, 12–14 mo old) C57BL6 mice. Intact retinal tissues were treated with MMP2 and -9 (~10 μg/mL total) for 1 h; protein immunoreactivity was assessed using anti-CNGA1 1D1 antibody or anti-MMP9 antibody. Channel subunit proteolytic band patterns differ between young and old mice in the absence of exogenous MMP application. (E) Analysis of MMP9 in these retinas demonstrated elevated levels of a ~65 kDa active form of MMP9 in the old retinas compared with young retinas. (F) MMP9/2 exposure was associated with only a slight increase in the apparent ~50 kDa CNGA1 proteolytic band in the detergent soluble fraction (Left); however, MMP exposure led to a significant increase in the apparent ~30 kDa band in the urea-soluble retinal fraction (Right). This is also a constitutive band (present in tissues not exposed to exogenous MMPs) in both young and old detergent-soluble retinal fractions (F, light gray arrow), and is visible with longer film exposures in the urea-soluble fractions (data not shown).
	Figure 12. Allosteric model.

Agrawal, MMPs in the central nervous system: where the good guys go bad. 2008, Pubmed

Agrawal, MMPs in the central nervous system: where the good guys go bad. 2008, Pubmed
Ahuja, rd1 mouse retina shows imbalance in cellular distribution and levels of TIMP-1/MMP-9, TIMP-2/MMP-2 and sulfated glycosaminoglycans. 2006, Pubmed
Biel, Function and dysfunction of CNG channels: insights from channelopathies and mouse models. 2007, Pubmed
Bilousova, Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. 2006, Pubmed
Bright, Regulation of human cone cyclic nucleotide-gated channels by endogenous phospholipids and exogenously applied phosphatidylinositol 3,4,5-trisphosphate. 2007, Pubmed , Xenbase
Chen, MMP9 is involved in glycation end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline. 2008, Pubmed
Chen, A new subunit of the cyclic nucleotide-gated cation channel in retinal rods. 1993, Pubmed , Xenbase
Chen, Subunit 2 (or beta) of retinal rod cGMP-gated cation channel is a component of the 240-kDa channel-associated protein and mediates Ca(2+)-calmodulin modulation. 1994, Pubmed
Chintala, The emerging role of proteases in retinal ganglion cell death. 2006, Pubmed
Conant, Methamphetamine-associated cleavage of the synaptic adhesion molecule intercellular adhesion molecule-5. 2011, Pubmed
Conant, Matrix metalloproteinase-dependent shedding of intercellular adhesion molecule-5 occurs with long-term potentiation. 2010, Pubmed
Craven, CNG and HCN channels: two peas, one pod. 2006, Pubmed
Faillace, Cellular processing of cone photoreceptor cyclic GMP-gated ion channels: a role for the S4 structural motif. 2004, Pubmed
Fodor, Mechanism of tetracaine block of cyclic nucleotide-gated channels. 1997, Pubmed , Xenbase
Fox, Calcium overload triggers rod photoreceptor apoptotic cell death in chemical-induced and inherited retinal degenerations. 1999, Pubmed
Garcia-Caballero, Activation of the epithelial sodium channel by the metalloprotease meprin β subunit. 2011, Pubmed , Xenbase
Gerstner, Molecular cloning and functional characterization of a new modulatory cyclic nucleotide-gated channel subunit from mouse retina. 2000, Pubmed
Giebel, Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. 2005, Pubmed
Gordon, Altered ligand specificity by protonation in the ligand binding domain of cyclic nucleotide-gated channels. 1996, Pubmed , Xenbase
Gordon, Localization of regions affecting an allosteric transition in cyclic nucleotide-activated channels. 1995, Pubmed , Xenbase
Haynes, Single cyclic GMP-activated channel activity in excised patches of rod outer segment membrane. , Pubmed
Huang, Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. 1995, Pubmed
Jones, Characterization and novel activation of 72-kDa metalloproteinase in retinal interphotoreceptor matrix and Y-79 cell culture medium. 1994, Pubmed
Kaupp, Primary structure and functional expression from complementary DNA of the rod photoreceptor cyclic GMP-gated channel. 1989, Pubmed , Xenbase
Kim, Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis. 2005, Pubmed
Kitamura, Regulation of renal sodium handling through the interaction between serine proteases and serine protease inhibitors. 2010, Pubmed
Kleyman, ENaC at the cutting edge: regulation of epithelial sodium channels by proteases. 2009, Pubmed
Ko, Developmental expression of retinal cone cGMP-gated channels: evidence for rapid turnover and trophic regulation. 2001, Pubmed
Ko, Circadian regulation of cGMP-gated cationic channels of chick retinal cones. Erk MAP Kinase and Ca2+/calmodulin-dependent protein kinase II. 2001, Pubmed
Körschen, A 240 kDa protein represents the complete beta subunit of the cyclic nucleotide-gated channel from rod photoreceptor. 1995, Pubmed
Kowluru, Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras. 2010, Pubmed
Li, Cyclic nucleotide-gated channels: structural basis of ligand efficacy and allosteric modulation. 1997, Pubmed
Liu, Functional consequences of progressive cone dystrophy-associated mutations in the human cone photoreceptor cyclic nucleotide-gated channel CNGA3 subunit. 2005, Pubmed , Xenbase
Liutkeviciene, Factors determining age-related macular degeneration: a current view. 2010, Pubmed
Macgregor, Tissue inhibitor of matrix metalloproteinase-3 levels in the extracellular matrix of lung, kidney, and eye increase with age. 2009, Pubmed
Majka, The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. 2001, Pubmed
Mali, Intravitreous injection of a membrane depolarization agent causes retinal degeneration via matrix metalloproteinase-9. 2005, Pubmed
Mathalone, The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. 2007, Pubmed
Meighan, Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses. 2007, Pubmed
Meighan, Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. 2006, Pubmed
Michaluk, Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. 2009, Pubmed
Miller, Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. 2010, Pubmed
Molday, The cGMP-gated channel of the rod photoreceptor cell characterization and orientation of the amino terminus. 1991, Pubmed , Xenbase
Molokanova, Modulation of rod photoreceptor cyclic nucleotide-gated channels by tyrosine phosphorylation. 1997, Pubmed , Xenbase
Molokanova, Activity-dependent modulation of rod photoreceptor cyclic nucleotide-gated channels mediated by phosphorylation of a specific tyrosine residue. 1999, Pubmed , Xenbase
Murphy, Progress in matrix metalloproteinase research. 2008, Pubmed
Nagy, Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. 2006, Pubmed
Nagy, The extracellular protease matrix metalloproteinase-9 is activated by inhibitory avoidance learning and required for long-term memory. 2007, Pubmed
Newman, Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. 1994, Pubmed
Okada, A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. 1986, Pubmed
Olson, Hippocampal MMP-3 elevation is associated with passive avoidance conditioning. 2008, Pubmed
Padgett, Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation. 1997, Pubmed
Papp, Visible light induces matrix metalloproteinase-9 expression in rat eye. 2007, Pubmed
Paquet-Durand, A key role for cyclic nucleotide gated (CNG) channels in cGMP-related retinitis pigmentosa. 2011, Pubmed
Pauly, Activity-dependent shedding of the NMDA receptor glycine binding site by matrix metalloproteinase 3: a PUTATIVE mechanism of postsynaptic plasticity. 2008, Pubmed
Payne, A mutation in guanylate cyclase activator 1A (GUCA1A) in an autosomal dominant cone dystrophy pedigree mapping to a new locus on chromosome 6p21.1. 1998, Pubmed
Peng, Functionally important calmodulin-binding sites in both NH2- and COOH-terminal regions of the cone photoreceptor cyclic nucleotide-gated channel CNGB3 subunit. 2003, Pubmed , Xenbase
Peng, Subunit configuration of heteromeric cone cyclic nucleotide-gated channels. 2004, Pubmed , Xenbase
Pifferi, Cyclic nucleotide-gated ion channels in sensory transduction. 2006, Pubmed
Plantner, Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. 1998, Pubmed
Plantner, Polarized distribution of metalloproteinases in the bovine interphotoreceptor matrix. 1994, Pubmed
Plantner, Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. 1998, Pubmed
Puente, Human and mouse proteases: a comparative genomic approach. 2003, Pubmed
Pugh, Amplification and kinetics of the activation steps in phototransduction. 1993, Pubmed
Rangaraju, Potassium channel modulation by a toxin domain in matrix metalloprotease 23. 2010, Pubmed
Ruiz, The single-channel dose-response relation is consistently steep for rod cyclic nucleotide-gated channels: implications for the interpretation of macroscopic dose-response relations. 1999, Pubmed , Xenbase
Schoenmakers, CHELATOR: an improved method for computing metal ion concentrations in physiological solutions. 1992, Pubmed
Sivak, MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. 2002, Pubmed
Smine, Membrane type-1 matrix metalloproteinase in human ocular tissues. 1997, Pubmed
Szklarczyk, MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function. 2008, Pubmed
Szklarczyk, Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. 2002, Pubmed
Tian, Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. 2007, Pubmed
Varnum, Molecular mechanism for ligand discrimination of cyclic nucleotide-gated channels. 1995, Pubmed
Wang, Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. 2008, Pubmed
Weitz, Subunit stoichiometry of the CNG channel of rod photoreceptors. 2002, Pubmed
Wójtowicz, Late phase of long-term potentiation in the mossy fiber-CA3 hippocampal pathway is critically dependent on metalloproteinases activity. 2010, Pubmed
Yang, Multiple roles of metalloproteinases in neurological disorders. 2011, Pubmed
Yu, Molecular cloning, functional expression and chromosomal localization of a human homolog of the cyclic nucleotide-gated ion channel of retinal cone photoreceptors. 1996, Pubmed
Zhang, Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration. 2004, Pubmed
Zheng, Rod cyclic nucleotide-gated channels have a stoichiometry of three CNGA1 subunits and one CNGB1 subunit. 2002, Pubmed , Xenbase
Zhong, The heteromeric cyclic nucleotide-gated channel adopts a 3A:1B stoichiometry. 2002, Pubmed